TopoⅡ、GST-π、P-gp在乳腺癌的表达及意义

Expression and significance of TopoⅡ,GST-π,P-gp in breast carcinoma

目的探讨几种多药耐药机制与乳腺浸润性导管癌的耐药性及临床病理特征的关系。方法应用免疫组化S-P法检测DNA拓扑异构酶Ⅱ、谷胱甘肽-S-转移酶-π和P-糖蛋白在220例乳腺浸润性导管癌组织中的表达。结果乳腺浸润性导管癌病例GST-π、P-gp均有较高的阳性率,TopoⅡ有近一半的病例不表达。TopoⅡ、GST-π和P-gp的表达与乳腺浸润性导管癌的分级、淋巴结转移无明显相关性(P>0.05)。结论乳腺浸润性导管癌的多药耐药与TopoⅡ、GST-π、P-gp的耐药机制有关。乳腺浸润性导管癌组织TopoⅡ、GST-π、P-gp的表达可作为指导乳腺浸润性导管癌化疗的重要指标和判断乳腺浸润性导管癌预后的参考指标。

Objective To study the expression and significance of DNA topoisomerase Ⅱ （Topo Ⅱ ）, gluta thione-S-tranferase-π （ GST-π ）and P-glycoprotein（P-gp ）in breast carcinoma. Methods The expression of Topo Ⅱ,GST-π and P-gp were studied by immunohistochemical technique （S-P method）in 220 cases of breast invasive ductal carcinoma （None of the patients had received prior chemotherapy or radiotherapy）. Results Positive expression of the Topo Ⅱ was observed in 126 of 220 cases of breast invasive ductal carcinoma （57.27%）. Positive expression of the GST -π was observed in 76 of 220 cases of breast invasive ductal carcinoma （34.55%）. Positive expression of P-gp was observed in 112 of 220 cases breast invasive ductal carcinoma（50.91% ）.The level of Topo Ⅱ, GST-π and P-gp expression were not associated with histologic grade and lymph node metastases in breast invasive ductal carcinoma（P〉0.05）.Conclusion Expression of Topo Ⅱ ,GST-π and P-gp in carcinomatous tissue has an instructive significance for chemotherapy of breast invasive ductal carcinoma.